The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
about
A Novel Epi-drug Therapy Based on the Suppression of BET Family Epigenetic Readers.Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer.BET inhibitors as novel therapeutic agents in breast cancer.Targeting bromodomain and extraterminal proteins in breast cancer.A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort.The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge
P2860
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The bromodomain inhibitor OTX0 ...... n combination with everolimus.
@en
The bromodomain inhibitor OTX015
@nl
type
label
The bromodomain inhibitor OTX0 ...... n combination with everolimus.
@en
The bromodomain inhibitor OTX015
@nl
prefLabel
The bromodomain inhibitor OTX0 ...... n combination with everolimus.
@en
The bromodomain inhibitor OTX015
@nl
P2093
P2860
P50
P356
P1433
P1476
The bromodomain inhibitor OTX0 ...... n combination with everolimus.
@en
P2093
Andrea Rinaldi
Elodie Odore
Esteban Cvitkovic
Eugenio Erba
Francesco Bertoni
Lucile Astorgues-Xerri
María E Riveiro
Mohamed Bekradda
Nicolò Panini
P2860
P304
P356
10.18632/ONCOTARGET.13814
P407
P577
2016-12-07T00:00:00Z